Total Payments
$1,391
2024 Payments
$418.21
Companies
24
Transactions
67
Medicare Patients
25,073
Medicare Billing
$5.2M
Payment Breakdown by Category
Food & Beverage$1,268 (91.2%)
Education$122.97 (8.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,268 | 63 | 91.2% |
| Education | $122.97 | 4 | 8.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $380.20 | 15 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $145.07 | 6 | $0 (2024) |
| Celgene Corporation | $138.92 | 6 | $0 (2024) |
| Daiichi Sankyo Inc. | $108.78 | 5 | $0 (2024) |
| Amgen Inc. | $82.65 | 4 | $0 (2023) |
| Merck Sharp & Dohme LLC | $68.84 | 6 | $0 (2024) |
| Incyte Corporation | $51.43 | 3 | $0 (2019) |
| Pharmacyclics LLC, An AbbVie Company | $48.96 | 2 | $0 (2023) |
| BIOPROTECT MEDICAL, INC. | $45.51 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $38.63 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $418.21 | 18 | Janssen Biotech, Inc. ($67.06) |
| 2023 | $188.98 | 9 | Daiichi Sankyo Inc. ($44.57) |
| 2022 | $67.01 | 3 | GENZYME CORPORATION ($28.62) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2020 | $208.37 | 7 | Janssen Biotech, Inc. ($168.10) |
| 2019 | $144.58 | 7 | Janssen Biotech, Inc. ($77.56) |
| 2018 | $178.99 | 12 | Janssen Biotech, Inc. ($36.70) |
| 2017 | $173.14 | 10 | Novartis Pharmaceuticals Corporation ($62.29) |
All Payment Transactions
67 individual payment records from CMS Open Payments — Page 3 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 07/06/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LYNPARZA | Food and Beverage | In-kind items and services | $4.40 | General |
| Category: ONCOLOGY | ||||||
| 05/03/2018 | Seattle Genetics, Inc. | ADCETRIS (Biological) | Education | In-kind items and services | $12.29 | General |
| Category: Oncology | ||||||
| 04/11/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $15.57 | General |
| Category: Hematology/Oncology | ||||||
| 04/04/2018 | Janssen Biotech, Inc. | Erleada (Drug), DARZALEX | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Oncology | ||||||
| 02/09/2018 | Amgen Inc. | Aranesp (Biological), Nplate, XGEVA | Food and Beverage | In-kind items and services | $22.24 | General |
| Category: Nephrology | ||||||
| 01/26/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Oncology | ||||||
| 01/05/2018 | Novartis Pharmaceuticals Corporation | SANDOSTATIN LAR (Drug) | Food and Beverage | In-kind items and services | $18.97 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2017 | Novartis Pharmaceuticals Corporation | KYMRIAH (Biological) | Food and Beverage | In-kind items and services | $48.89 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $15.33 | General |
| Category: Oncology | ||||||
| 06/22/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $18.22 | General |
| Category: ONCOLOGY | ||||||
| 06/13/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.90 | General |
| Category: Hematology/Oncology | ||||||
| 06/06/2017 | Novartis Pharmaceuticals Corporation | JADENU (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: HEMATOLOGY | ||||||
| 04/27/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $10.77 | General |
| Category: Oncology | ||||||
| 03/23/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: ONCOLOGY | ||||||
| 02/23/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $12.38 | General |
| Category: Oncology | ||||||
| 02/07/2017 | Janssen Biotech, Inc. | IMBRUVICA (Drug), DARZALEX | Food and Beverage | In-kind items and services | $11.18 | General |
| Category: Oncology | ||||||
| 01/26/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $10.26 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 67 | 4,055 | 54,017 | $4.7M | $1.1M |
| 2022 | 70 | 4,598 | 89,251 | $5.9M | $1.4M |
| 2021 | 87 | 7,404 | 108,180 | $6.6M | $1.5M |
| 2020 | 87 | 9,016 | 87,913 | $5.8M | $1.2M |
Total Patients
25,073
Total Services
339,361
Medicare Billing
$5.2M
Procedure Codes
311
All Medicare Procedures & Services
311 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 30 | 12,420 | $1.5M | $472,036 | 31.9% |
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 7,500 | $1.1M | $323,092 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 425 | 819 | $153,180 | $61,126 | 39.9% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 17 | 1,470 | $285,180 | $32,663 | 11.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 122 | 235 | $163,982 | $28,767 | 17.5% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 20 | 9,260 | $194,460 | $21,766 | 11.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 82 | 145 | $33,570 | $14,627 | 43.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 430 | 1,390 | $86,180 | $14,332 | 16.6% |
| 83883 | Nephelometry, test method using light | Office | 2023 | 125 | 862 | $151,712 | $11,467 | 7.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 69 | 170 | $53,123 | $11,414 | 21.5% |
| 88185 | Flow cytometry technique for dna or cell analysis, each additional marker | Office | 2023 | 19 | 480 | $84,000 | $10,992 | 13.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 291 | 1,364 | $47,740 | $10,327 | 21.6% |
| J1454 | Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | Office | 2023 | 23 | 30 | $55,350 | $10,244 | 18.5% |
| 86334 | Immunologic analysis technique on serum (immunofixation) | Office | 2023 | 130 | 430 | $68,800 | $9,394 | 13.7% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 13 | 9,750 | $48,750 | $8,564 | 17.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 64 | 72 | $18,864 | $8,192 | 43.4% |
| M0010 | Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 2023 | 19 | 111 | $7,770 | $7,615 | 98.0% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 97 | 774 | $41,796 | $7,054 | 16.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 39 | $16,365 | $5,884 | 36.0% |
| 82232 | Beta-2 microglobulin (protein) level | Office | 2023 | 103 | 363 | $33,759 | $5,743 | 17.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 63 | 63 | $15,249 | $5,563 | 36.5% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 83 | 110 | $12,748 | $5,107 | 40.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 54 | 71 | $11,199 | $4,763 | 42.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 44 | 78 | $26,739 | $4,739 | 17.7% |
| 84165 | Protein measurement, serum | Office | 2023 | 130 | 434 | $41,664 | $4,561 | 10.9% |
About Dr. Gregory Orloff, M.D
Dr. Gregory Orloff, M.D is a Hematology & Oncology healthcare provider based in Fairfax, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1750358776.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Orloff, M.D has received a total of $1,391 in payments from pharmaceutical and medical device companies, with $418.21 received in 2024. These payments were reported across 67 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,268).
As a Medicare-enrolled provider, Orloff has provided services to 25,073 Medicare beneficiaries, totaling 339,361 services with total Medicare billing of $5.2M. Data is available for 4 years (2020–2023), covering 311 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Fairfax, VA
- Active Since 03/08/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1750358776
Products in Payments
- DARZALEX (Biological) $145.05
- ERLEADA (Drug) $143.82
- KEYTRUDA (Biological) $63.16
- INJECTAFER (Drug) $59.13
- REBLOZYL (Biological) $55.54
- JAKAFI (Drug) $51.43
- Enhertu (Drug) $49.65
- KYMRIAH (Biological) $48.89
- IMBRUVICA (Drug) $45.74
- BIOPROTECT BALLOON IMPLANT SYSTEM (Device) $45.51
- OPDIVO (Biological) $38.63
- TAGRISSO (Drug) $38.48
- JEVTANA (Drug) $28.62
- Fabhalta (Drug) $25.20
- Kyprolis (Drug) $25.05
- KISQALI (Drug) $23.76
- TECVAYLI (Biological) $23.46
- Tibsovo (Drug) $23.44
- TALVEY (Biological) $23.10
- Aranesp (Biological) $22.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Fairfax
Dr. William Ershler, M.d, M.D
Hematology & Oncology — Payments: $143,157
Hematology & Oncology $143,157
Nagla Abdel Karim, Md, MD
Hematology & Oncology — Payments: $126,207
Hematology & Oncology $126,207
Dipti Patel-Donnelly, M.d, M.D
Hematology & Oncology — Payments: $46,716
Hematology & Oncology $46,716
Nicholas Robert, M.d, M.D
Hematology & Oncology — Payments: $34,071
Hematology & Oncology $34,071
Daniel Chong, M.d, M.D
Hematology & Oncology — Payments: $19,434
Hematology & Oncology $19,434
Timothy Mccarthy, M.d, M.D
Hematology & Oncology — Payments: $7,653
Hematology & Oncology $7,653